27 results
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
27 Mar 24
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
7:30am
of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
27 Sep 23
Regulation FD Disclosure
4:43pm
Cell market research.
Be The Match® website (accessed 5/30/23); IT-Ideation Department, February 2021 (ethnic background %).
Contraindications
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
17 Apr 23
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
5:29pm
://bethematch.org/transplant-basics/how-blood-stem-cell-transplants-work/how-does-a-patients-ethnic-
background-affect-matching/
Important Safety
8-K
EX-99.1
80d4a 95j
14 Nov 22
Gamida Cell Reports Third Quarter 2022 Financial Results
7:15am
424B5
j2irxb 1c8w2l
29 Sep 22
Prospectus supplement for primary offering
4:08pm
424B5
sfty2mt6v90fw nn6m09
27 Sep 22
Prospectus supplement for primary offering
5:01pm
10-Q
bzco0292pu1ss egzkim
12 May 22
Quarterly report
7:42am
8-K
EX-99.1
xft5yre9
10 May 22
Gamida Cell Reports First Quarter 2022 Financial Results
7:30am
10-K
358v epjbmnb17z
24 Mar 22
Annual report
7:30am
6-K
EX-99.1
kixfadx jml
11 May 21
Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company Update
8:28am
6-K
EX-99.1
2xjmewqzb 4zvx9
10 Feb 21
Current report (foreign)
4:01pm
424B4
3eetqe6g7fm375ngxhpp
28 Jun 19
Prospectus supplement with pricing info
3:51pm
F-1/A
hmvz6fyoayrm5m18bi21
26 Jun 19
Registration statement (foreign) (amended)
12:00am
F-1
9l1wei
24 Jun 19
Registration statement (foreign)
4:04pm